Vimarsana
Biggest News Aggregation in the World

Page 2 - Aim Leukemia News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Aim Leukemia. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Aim Leukemia Today - Breaking & Trending Today

Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Vimarsana News

Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

LEXINGTON, Mass., Oct. 6, 2023 /PRNewswire/ -- Curis, Inc. , a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that on...

Curis to Present at Upcoming Healthcare Conferences in September - Vimarsana News

Curis to Present at Upcoming Healthcare Conferences in September

LEXINGTON, Mass., Sept. 6, 2023 /PRNewswire/ -- Curis, Inc. , a biotechnology company focused on the development of emavusertib, an orally available small molecule IRAK4 inhibitor for the treatment...

Curis Provides Second Quarter 2023 Business Update - Vimarsana News

Curis Provides Second Quarter 2023 Business Update

Removal of partial clinical hold – enrolling patients at confirmed RP2D in the TakeAim Leukemia Study Enrolling patients in the TakeAim Lymphoma Study in combination with ibrutinib Strong balance...

Curis to Release Second Quarter 2023 Financial Results and Hold Conference Call on August 3, 2023 - Vimarsana News

Curis to Release Second Quarter 2023 Financial Results and Hold Conference Call on August 3, 2023

LEXINGTON, Mass., July 27, 2023 /PRNewswire/ -- Curis, Inc. , a biotechnology company focused on the development of emavusertib, an orally available, small molecule IRAK4 inhibitor for the treatment...

Curis, Inc. - FDA Removes Partial Clinical Hold on TakeAim Leukemia Study RP2D Established at 300 mg BID - Vimarsana News

Curis, Inc. - FDA Removes Partial Clinical Hold on TakeAim Leukemia Study RP2D Established at 300 mg BID

LEXINGTON - Curis, Inc., , a biotechnology company focused on the development of emavusertib, an orally available small molecule triple target inhibitor for the treatment of hematologic...